Delinea Named a Leader in 2024 Gartner ® Magic Quadrant™ for Privileged Access Management
Delinea, a pioneering provider of solutions for securing identities through centralized authorization, today announced its recognition as a Leader in the 2024 Gartner Magic Quadrant for Privileged Access Management (PAM). This marks the 6th consecutive time that Delinea has been acknowledged in the Leaders Quadrant; Delinea stated that, in their opinion, this highlights the company's ongoing commitment to delivering market-trusted security solutions.
“We are honored to be recognized once again as a Leader by Gartner,” said Art Gilliland, CEO of Delinea. “Identity security serves as the first line of defense, as every identity, both human and non-human, and the data with which they interact are targets in today’s modern enterprises. I believe this acknowledgement reaffirms our commitment to safeguarding our clients while delivering solutions that not only enhance security but also remove complexity, elevating the user experience.”
As Gartner states, “growth continues to be driven by the increasing awareness among security and identity leaders regarding the critical need for PAM solutions. Leaders have successfully built a significant installed customer base and revenue stream and have high viability ratings and robust revenue growth”.
Delinea's cloud-native platform delivers a comprehensive suite of integrated solutions, encompassing Privileged Account and Session Management (PASM), Privileged Elevation and Delegation Management (PEDM), Remote Privileged Access Management (RPAM), Cloud Infrastructure Entitlement Management (CIEM), and Identity Threat Detection and Response (ITDR), to provide a seamless and intuitive user experience.
With its intelligent authorization capabilities, Delinea empowers organizations to discover identities, assign access levels, detect irregularities, and respond to threats in real time. The platform is engineered for rapid deployment in weeks rather than months and demands 90% fewer resources to manage compared to competitors' solutions.
For complimentary access to the 2024 Gartner Magic Quadrant for Privileged Access Management and to learn more about why Delinea was named a Leader, visit our website.
Required Disclaimer:
Gartner, Magic Quadrant for Privileged Access Management, Abhyuday Data, et al, 9 September 2024 GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally, and MAGIC QUADRANT is a registered trademark of Gartner, Inc. and/or its affiliates and are used herein with permission. All rights reserved.
Gartner does not endorse any vendor, product, or service depicted in its research publications and does not advise technology users to select only those vendors with the highest ratings or other designations. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
Delinea was formed in April 2021 through the merger of Thycotic and Centrify and was named a Leader in the 2022 and 2023 Gartner Magic Quadrant for PAM.Centrify was named a Leader in the 2018, 2020, and 2021 reports. Thycotic was named a Leader in the 2020 and 2021 reports.
About Delinea
Delinea is a pioneer in securing identities through centralized authorization, making organizations more secure by seamlessly governing their interactions across modern enterprise. It applies context and intelligence throughout the identity lifecycle, covering cloud and traditional infrastructure, data, and SaaS applications to eliminate identity-related threats. Delinea uniquely provides intelligent authorization for all identities, allowing precise user identification, appropriate access assignment, interaction monitoring, and swift response to irregularities. The Delinea Platform accelerates adoption and boosts productivity, deploying in weeks, not months, requiring just 10% of the resources compared to competitors. Discover more about Delinea on Delinea.com, LinkedIn, X, and YouTube.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240911991823/en/
Contacts
Media Contacts:
Frances Fenemore
Vice President, Marketing Communications
frances.fenemore@delinea.com
m: +44 7399 111299
Hotwire Global Communications
delinea@hotwireglobal.com (US)
delineauk@hotwireglobal.com (UK)
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kweichow Moutai’s Brand Culture Activities in Greece Foster Sino-Greek Cultural Cooperation21.12.2024 20:41:00 EET | Press release
On December 9th, the exhibition “Longevity in the Tao of Chrysanthemum: The Artistic World of Qi Baishi,” supported by Kweichow Moutai Group, opened at the Athens University History Museum. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241221429801/en/ Gao Shan(R3), and Petros Tatoulis(R2), took a group photo with other guests at the opening ceremony of the exhibition. (Photo: Business Wire) Featuring the works of Qi Baishi, a renowned Chinese painter, the exhibition highlights the unique charm of traditional Chinese culture for Western audiences, while advancing cultural exchange and mutual understanding between China and Greece. Gao Shan, Chairman of the Labor Union at Kweichow Moutai Distillery (Group) Co., Ltd., remarked on the significance of the event, saying, “Qi Baishi employed distinctive Eastern painting techniques to convey the Chinese perspective of the world. Athens, a city celebrated for its great masters and
Vertex Announces US FDA Approval of ALYFTREK ™ , a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis20.12.2024 22:46:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for the treatment of cystic fibrosis (CF) in people 6 years and older who have at least one F508del mutation or another mutation in the CFTR gene that is responsive to ALYFTREK. See below for Important Safety Information, including a Boxed Warning. “ALYFTREK is our fifth CFTR modulator to secure FDA approval and represents another significant milestone in our journey to serially innovate and to improve the lives of people living with cystic fibrosis,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “Our north star for more than 20 years has been to address the underlying cause of cystic fibrosis, treat more people with this disease, and bring more people to normal le
Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non- F508del TRIKAFTA-Responsive Variants20.12.2024 22:35:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 2 and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation that is responsive to TRIKAFTA based on clinical and/or in vitro data. In addition, safety information on liver injury and liver failure has been updated from warnings and precautions to a boxed warning. With this approval, 94 additional non-F508delCFTR mutations have been added to the TRIKAFTA label, and approximately 300 additional people with CF in the U.S. are now eligible for a medicine to treat the underlying cause of their disease for the first time. “Since its first approval in 2019, TRIKAFTA has had a transformative impact on tens of thousands of people living with cystic fibrosis,” sai
HSBC Continental Europe Enters Into a Memorandum of Understanding Regarding Potential Sale of HSBC Assurances Vie (France) to Matmut Société d’Assurance Mutuelle20.12.2024 21:32:00 EET | Press release
Regulatory News: HSBC Continental Europe has signed a Memorandum of Understanding (‘MOU‘) regarding the potential sale of its French life insurance business, HSBC Assurances Vie (France), to Matmut Société d’Assurance Mutuelle (‘Matmut’) (the “Potential Transaction”). HSBC Assurances Vie (France) provides a wide range of life insurance solutions and services, with over 20 billion euros of outstanding assets, net income1 of 77 million euros and a Solvency II ratio of 287% in 2023. As part of the Potential Transaction, HSBC Continental Europe and Matmut would enter into a long-term arrangement for HSBC Global Asset Management (France) to continue to partner with HSBC Assurances Vie (France). HSBC Assurances Vie (France) will continue its existing distribution arrangements. The Potential Transaction would provide customers and employees of HSBC Insurance Life (France) with the opportunity to join one of the leading French mutual insurance groups, which is in full development, and forms pa
Aarhus University: New Global Study Sheds Light on the Learning Crisis: Three Years After COVID-1920.12.2024 14:00:00 EET | Press release
TIMSS 2023 has revealed an alarming global learning crisis exacerbated by the COVID-19 pandemic. Compared to the long term trend in progress in mathematics and science achievement has not only stalled but reversed when taking school closures into account, with the most vulnerable students facing the steepest losses. Key Findings Global Achievement Decline: A 0.11 standard deviation drop in student performance reflects the pandemic's lasting impact. Disproportionate Impact: Low performers, girls, and language minorities faced losses up to twice the average (0.22 standard deviations), deepening existing inequities. Regional Variations: Countries with prolonged school closures and limited remote learning resources experienced the steepest declines. Why This Matters School closures disrupted the education of over one billion children worldwide, with disadvantaged students suffering the most. “The widening gender gap in STEM fields is particularly troubling,” said Christian Kjeldsen, incomi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom